Dompé expand Commercial Operations for Oxervate to Canada.
October 11, 2021
La collaborazione trasforma la ricerca in business
September 15, 2021
Dompé farmaceutici: continuiamo ad assumere e investire per mantenere eccellenza e competitività
July 29, 2021
Comunicazione partecipazione al capitale sociale di Philogen S.p.A.
July 20, 2021
Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia
June 3, 2021
Leonardo and Dompé launch the first, national digital health security infrastructure with Cloud architecture
April 21, 2021
LIGATE: NEW EUROPEAN BACKED EFFORT AGAINST PANDEMICS KICKS OFF WITH 5,9 MLN €
February 16, 2021
Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)
January 14, 2021
DOMPÉ AND THE FARMAMONDO GROUP: EXSCLUSIVE AGREEMENT TO DISTRIBUTE OXERVATE™ IN RUSSIA AND OTHER CIS COUNTRIES
November 26, 2020
Exscalate4Cov performed in Italy the most complex supercomputing experiment to identify new therapies against Sars Cov2 virus.
November 23, 2020